Key Takeaways
- • Jeito Capital closed its second fund at $1.2 billion, establishing a record for the largest raise by an independent European biopharma-focused fund, exceeding its original target.
- • The Paris-based firm nearly doubled its capital base from the €534 million raised for its inaugural fund in 2021, expanding its investment scope from 12-15 to 15-20 portfolio companies.
- • Jeito II will deploy significantly larger per-company investments, increasing average ticket size to €150 million ($175 million), enabling portfolio companies to accelerate clinical development and advance toward commercialization.
- • The fund maintains its core strategy of targeting clinical-stage European biotech firms developing breakthrough therapies for severe diseases with high unmet medical needs.
- • Founder and President Rafaèle Tordjman highlighted the raise as validation of European biopharma innovation capacity and the ecosystem's ability to generate major therapeutic breakthroughs with adequate capital and strategic support.
Summary
Jeito Capital has successfully closed its second fund at $1.2 billion, marking what the firm describes as the largest capital raise achieved by a fully independent European biopharma investment fund. The Paris-based private equity vehicle exceeded its initial fundraising target, demonstrating strong institutional investor confidence in its clinical-stage biotech investment thesis and track record.
The capital raise represents a significant expansion from Jeito's first fund, which accumulated €534 million in 2021. With capital nearly doubled, Jeito II will expand its portfolio construction strategy to deploy capital across 15 to 20 biopharma companies, compared to the 12-15 company range targeted for its inaugural fund. This broader investment footprint allows the firm to diversify risk while maintaining its specialized focus on the European clinical-stage biotech sector.
A key strategic implication of the larger fund size is Jeito's ability to increase per-company investment commitments to approximately €150 million ($175 million) per portfolio company. According to the firm's April 8 release, this enhanced capital deployment capacity will enable portfolio companies to "accelerate and progress through to advanced clinical development and unleash their full commercial potential," reducing time-to-market and de-risking the pathway to regulatory approval and commercialization.
Jeito's investment focus remains concentrated on European clinical-stage companies developing breakthrough therapies addressing severe diseases with high unmet medical needs. The firm applies a patient-driven investment strategy emphasizing acceleration of development timelines and future market access optimization. Rafaèle Tordjman, founder and president, characterized the successful raise as "a strong signal for the European biopharma ecosystem," underscoring growing institutional conviction that European-based companies possess the capacity to drive major therapeutic innovation and generate substantial economic benefits when provided adequate financial resources and strategic guidance.
The capital raise represents a significant expansion from Jeito's first fund, which accumulated €534 million in 2021. With capital nearly doubled, Jeito II will expand its portfolio construction strategy to deploy capital across 15 to 20 biopharma companies, compared to the 12-15 company range targeted for its inaugural fund. This broader investment footprint allows the firm to diversify risk while maintaining its specialized focus on the European clinical-stage biotech sector.
A key strategic implication of the larger fund size is Jeito's ability to increase per-company investment commitments to approximately €150 million ($175 million) per portfolio company. According to the firm's April 8 release, this enhanced capital deployment capacity will enable portfolio companies to "accelerate and progress through to advanced clinical development and unleash their full commercial potential," reducing time-to-market and de-risking the pathway to regulatory approval and commercialization.
Jeito's investment focus remains concentrated on European clinical-stage companies developing breakthrough therapies addressing severe diseases with high unmet medical needs. The firm applies a patient-driven investment strategy emphasizing acceleration of development timelines and future market access optimization. Rafaèle Tordjman, founder and president, characterized the successful raise as "a strong signal for the European biopharma ecosystem," underscoring growing institutional conviction that European-based companies possess the capacity to drive major therapeutic innovation and generate substantial economic benefits when provided adequate financial resources and strategic guidance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.